Introduction:
Mandaya Royal Hospital Puri (MRHP) stands as a beacon of excellence in the Indonesian healthcare landscape. With a commitment to providing world-class medical care, MRHP, part of the esteemed Mandaya Hospital Group, has set a new standard for private healthcare facilities in Indonesia. Equipped with state-of-the-art technology and a dedicated team of highly trained medical professionals, MRHP caters to the diverse healthcare needs of patients, delivering not just clinical care but a holistic patient experience. This is the story of MRHP’s pursuit of excellence in cancer diagnostics and personalized treatment through the integration of digital PCR technology, specifically Unicorn Digital PCR, into their clinical laboratory.
The Need for Advanced Molecular Diagnostics:
In an age of personalized medicine and targeted therapy, the demand for ultra-sensitive molecular diagnostic methods has grown exponentially. Molecular techniques like Next-Generation Sequencing (NGS) and digital PCR have become pivotal tools in cancer genotyping, offering insights into tumor genetics that guide treatment decisions.
These methods are particularly crucial for the detection of cancer biomarkers in liquid biopsies, such as cell-free DNA, cell-free RNA, circulating tumor cells (CTCs), and extracellular vesicles. Digital PCR, in particular, has emerged as a gold standard in quantitative nucleic acid analysis, thanks to its precision and reliability.
Unicorn Digital PCR: Empowering Cancer Genotyping:
Mandaya Royal Hospital Puri recognized the importance of harnessing digital PCR technology to enhance their molecular diagnostics capabilities. Unicorn Digital PCR AccuONE-150 proved to be an invaluable addition to their clinical laboratory, allowing them to achieve new levels of accuracy and sensitivity in detecting critical cancer biomarkers.
- HER2 Amplification: Unicorn Digital PCR offers a solution to the challenge of false-negative results arising from irregular sample pretreatment. It ensures the accurate detection of HER2 amplification, a pivotal biomarker for breast cancer treatment, and allows for testing on peripheral blood samples. This dynamic monitoring of HER2 amplification in response to therapy provides early insights into the efficacy of treatment.
- PIK3CA Mutation: In the realm of early breast cancer, PIK3CA mutations are prevalent and have significant implications for treatment decisions. Unicorn’s multiplex digital PCR technology swiftly and cost-effectively detects common pathogenic PIK3CA mutations with exceptional sensitivity and specificity, covering up to 90% of cases. The platform’s ability to detect low-frequency mutations with unparalleled precision positions it as an indispensable tool for genetic testing and personalized treatment.
Mandaya Royal Hospital Puri’s Vision:
By integrating Unicorn Digital PCR into their diagnostic framework, MRHP has established a comprehensive breast cancer diagnosis program. This program is centered on HER2 gene amplification and PIK3CA mutation detection, offering precise molecular diagnostic results that enable healthcare providers to make more informed therapeutic decisions. Ultimately, MRHP’s adoption of advanced molecular diagnostics exemplifies their unwavering commitment to elevating patient care and advancing the standards of healthcare in Indonesia.
Conclusion:
Mandaya Royal Hospital Puri’s journey with Unicorn Digital PCR is a testament to their dedication to offering the highest quality medical services. By embracing cutting-edge technology, they’ve not only enhanced their diagnostic capabilities but have also paved the way for more effective, personalized, and precise cancer treatments. This partnership between MRHP and Unicorn Digital PCR stands as a shining example of how innovation in healthcare can bring transformative benefits to patients and the medical community alike.
Clinical Information:
Unlock the Future of Cancer Diagnosis! Dive into the world of precision medicine with our exclusive clinical presentations on HER2 and PIK3CA genes, and discover groundbreaking research in our paper on detecting HER2 amplification in breast and gastric cancer patients using digital PCR. Stay ahead in the realm of molecular diagnostics – download now and join us in the pursuit of cutting-edge cancer care.
Know more about Unicorn Digital PCR:
